Main Paper on Molecular Marker Testing for Thyroid Nodules and Cancer

Main Paper on Molecular Marker Testing for Thyroid Nodules and Cancer

Main Paper on Molecular Marker Testing for Thyroid Nodules and Cancer

Main Paper on Molecular Marker Testing for Thyroid Nodules and Cancer

DR Guttler was a researcher on this major paper on the clinical use of cancer markers for thyroid nodules and cancer published in the journal Thyroid.

Centralized Molecular Testing for Oncogenic Gene Mutations Complements the Local Cytopathologic Diagnosis of Thyroid Nodules

To cite this article:
Beaudenon-Huibregtse Sylvie, Alexander Erik K., Guttler Richard B., Hershman Jerome M., Babu Varsha, Blevins Thomas C., Moore Paul, Andruss Bernard, and Labourier Emmanuel. Thyroid. October 2014, 24(10): 1479-1487. doi:10.1089/thy.2013.0640.

Author information

Sylvie Beaudenon-Huibregtse,1 Erik K. Alexander,2 Richard B. Guttler,3 Jerome M. Hershman,4,5 Varsha Babu,4 Thomas C. Blevins,6 Paul Moore,7 Bernard Andruss,1 and Emmanuel Labourier1
1Asuragen Inc., Austin, Texas.
2Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts.
3Santa Monica Thyroid Center, Santa Monica, California.
4Endocrinology and Diabetes Division, West Los Angeles Veterans Affairs Medical Center, Los Angeles, California.
5School of Medicine, University of California, Los Angeles, Los Angeles, California.
6Texas Diabetes and Endocrinology, Austin, Texas.
7The Austin Diagnostic Clinic, Austin, Texas.
Address correspondence to:
Emmanuel Labourier, PhD

Asuragen Inc.

2150 Woodward Street, Suite 100
Austin, TX 78744

E-mail:

ABSTRACT

Background: Molecular testing for oncogenic gene mutations and chromosomal rearrangements plays a growing role in the optimal management of thyroid nodules, yet lacks standardized testing modalities and systematic validation data. Our objective was to assess the performance of molecular cytology on preoperative thyroid nodule fine-needle aspirates (FNAs) across a broad range of variables, including independent collection sites, clinical practices, and anatomic pathology interpretations.

Methods: Single-pass FNAs were prospectively collected from 806 nodules 1 cm or larger by ultrasonography at five independent sites across the United States. Specimens were shipped in a nucleic acid stabilization solution and tested at a centralized clinical laboratory. Seventeen genetic alterations (BRAF, KRAS, HRAS, and NRAS mutations, PAX8-PPARG and RET-PTC rearrangements) were evaluated by multiplex polymerase chain reaction and liquid bead array cytometry in 769 FNAs that met inclusion criteria. Cytology, histology, and clinical care followed local procedures and practices. All results were double-blinded.

Results: Thirty-two specimens (4.2%) failed to yield sufficient nucleic acid to generate molecular data. A single genetic alteration was detected in 80% of cytology malignant cases, 21% of indeterminate, 7.8% of nondiagnostic, and 3.5% of benign cases. Among 109 nodules with surgical histology reference standard, oncogenic mutations were present in 50% of malignant nodules missed by cytology. There were 14 cancers not identified by cytology or molecular tests, including 5 carcinomas with histologic sizes less than 1 cm (3 multifocal) and 8 noninvasive follicular variants of papillary carcinoma (4 encapsulated). No mutations were detected in 89% of the nodules benign by histopathology with 6 false-positive molecular results in 5 adenomas (2–5.5 cm) and 1 cystic nodule with an incidental papillary microcarcinoma (0.15 cm). The posttest probability of thyroid cancer was 100% for nodules positive for BRAF or RET-PTC, 70% for RAS or PAX8-PPARG, and 88% for molecular cytology overall.

Conclusions: Centralized and standardized molecular testing for genetic alterations associated with a high risk of malignancy efficiently complements the local cytopathologic diagnosis of thyroid nodule aspirates in the clinical setting. Actionable molecular cytology can improve the personalized surgical and medical management of patients with thyroid cancers, facilitating one-stage total thyroidectomy and reducing the number of unnecessary diagnostic surgeries.

Add Your Comment

Contact Info
1328 16th Street, Santa Monica, CA 90404
Monday – Friday
9:00 AM to 5:00 PM
(310) 393-8860